For which indications are 177lu Dotatate peptide receptor radionuclide therapy approved by the FDA?

177Lu Dotatate (Lutathera) is a radiolabeled somatostatin analog peptide approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. Specifically, 177Lu Dotatate is indicated for:



Key points:

Indications Supported by Clinical Evidence

The NETTER-1 trial that supported FDA approval evaluated 177Lu Dotatate in patients with the following inclusion criteria:

The trial enrolled and treated patients with the following specific neuroendocrine tumor types:

177Lu Dotatate resulted in:

Based on these positive phase 3 results, FDA approval covers somatostatin receptor-positive GEP-NETs of the:

✔️ Foregut (e.g. lung, pancreas)

✔️ Midgut (e.g. small bowel)

✔️ Hindgut (e.g. colorectal)

This includes locally advanced, unresectable, or metastatic tumors.

Vitality Hormone Center Specializes in Neuroendocrine Tumors

If you have been diagnosed with a neuroendocrine tumor such as a GEP-NET, the hormone therapy experts at Vitality Hormone Center can help.

We specialize in using natural hormone balancing therapy and lifestyle changes to help patients improve their quality of life when facing illnesses like neuroendocrine tumors. Examples of our holistic programs include:

While 177Lu Dotatate provides proven benefits for treating advanced GEP-NETs, our goal is to support you through every step of the journey.

Contact Vitality Hormone Center today to learn how our personalized care programs can help you thrive in the face of adversity.

Experience personalized care for your neuroendocrine tumor.

Our Services

Get Free Consultation